Advanced search
1 file | 1.16 MB Add to list

Melatonin for rapid eye movement sleep behavior disorder in Parkinson's disease : a randomised controlled trial

(2020) MOVEMENT DISORDERS. 35(2). p.344-349
Author
Organization
Abstract
Background Melatonin may reduce REM-sleep behavior disorder (RBD) symptoms in Parkinson's disease (PD), though robust clinical trials are lacking. Objective To assess the efficacy of prolonged-release (PR) melatonin for RBD in PD. Methods Randomized, double-blind, placebo-controlled, parallel-group trial with an 8-week intervention and 4-week observation pre- and postintervention (ACTRN12613000648729). Thirty PD patients with rapid eye movement sleep behavior disorder were randomized to 4 mg of prolonged-release melatonin (Circadin) or matched placebo, ingested orally once-daily before bedtime. Primary outcome was the aggregate of rapid eye movement sleep behavior disorder incidents averaged over weeks 5 to 8 of treatment captured by a weekly diary. Data were included in a mixed-model analysis of variance (n = 15 per group). Results No differences between groups at the primary endpoint (3.4 events/week melatonin vs. 3.6 placebo; difference, 0.2; 95% confidence interval = -3.2 to 3.6; P = 0.92). Adverse events included mild headaches, fatigue, and morning sleepiness (n = 4 melatonin; n = 5 placebo). Conclusion Prolonged-release melatonin 4 mg did not reduce rapid eye movement sleep behavior disorder in PD. (c) 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Keywords
Neurology, Clinical Neurology, melatonin, Parkinson's disease, randomized controlled trial, REM sleep behavior disorder, sleep disorders, THERAPY, RAMELTEON, PATIENT

Downloads

  • published.pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 1.16 MB

Citation

Please use this url to cite or link to this publication:

MLA
Gilat, Moran, et al. “Melatonin for Rapid Eye Movement Sleep Behavior Disorder in Parkinson’s Disease : A Randomised Controlled Trial.” MOVEMENT DISORDERS, vol. 35, no. 2, 2020, pp. 344–49.
APA
Gilat, M., Coeytaux Jackson, A., Marshall, N. S., Hammond, D., Mullins, A. E., Hall, J., … Lewis, S. J. G. (2020). Melatonin for rapid eye movement sleep behavior disorder in Parkinson’s disease : a randomised controlled trial. MOVEMENT DISORDERS, 35(2), 344–349.
Chicago author-date
Gilat, Moran, Alessandra Coeytaux Jackson, Nathaniel S. Marshall, Deborah Hammond, Anna E. Mullins, Julie Hall, Bernard A.M. Fang, et al. 2020. “Melatonin for Rapid Eye Movement Sleep Behavior Disorder in Parkinson’s Disease : A Randomised Controlled Trial.” MOVEMENT DISORDERS 35 (2): 344–49.
Chicago author-date (all authors)
Gilat, Moran, Alessandra Coeytaux Jackson, Nathaniel S. Marshall, Deborah Hammond, Anna E. Mullins, Julie Hall, Bernard A.M. Fang, Brendon J. Yee, Keith K.H. Wong, Ron R. Grunstein, and Simon J. G. Lewis. 2020. “Melatonin for Rapid Eye Movement Sleep Behavior Disorder in Parkinson’s Disease : A Randomised Controlled Trial.” MOVEMENT DISORDERS 35 (2): 344–349.
Vancouver
1.
Gilat M, Coeytaux Jackson A, Marshall NS, Hammond D, Mullins AE, Hall J, et al. Melatonin for rapid eye movement sleep behavior disorder in Parkinson’s disease : a randomised controlled trial. MOVEMENT DISORDERS. 2020;35(2):344–9.
IEEE
[1]
M. Gilat et al., “Melatonin for rapid eye movement sleep behavior disorder in Parkinson’s disease : a randomised controlled trial,” MOVEMENT DISORDERS, vol. 35, no. 2, pp. 344–349, 2020.
@article{8649768,
  abstract     = {Background Melatonin may reduce REM-sleep behavior disorder (RBD) symptoms in Parkinson's disease (PD), though robust clinical trials are lacking. Objective To assess the efficacy of prolonged-release (PR) melatonin for RBD in PD. Methods Randomized, double-blind, placebo-controlled, parallel-group trial with an 8-week intervention and 4-week observation pre- and postintervention (ACTRN12613000648729). Thirty PD patients with rapid eye movement sleep behavior disorder were randomized to 4 mg of prolonged-release melatonin (Circadin) or matched placebo, ingested orally once-daily before bedtime. Primary outcome was the aggregate of rapid eye movement sleep behavior disorder incidents averaged over weeks 5 to 8 of treatment captured by a weekly diary. Data were included in a mixed-model analysis of variance (n = 15 per group). Results No differences between groups at the primary endpoint (3.4 events/week melatonin vs. 3.6 placebo; difference, 0.2; 95% confidence interval = -3.2 to 3.6; P = 0.92). Adverse events included mild headaches, fatigue, and morning sleepiness (n = 4 melatonin; n = 5 placebo). Conclusion Prolonged-release melatonin 4 mg did not reduce rapid eye movement sleep behavior disorder in PD. (c) 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.},
  author       = {Gilat, Moran and Coeytaux Jackson, Alessandra and Marshall, Nathaniel S. and Hammond, Deborah and Mullins, Anna E. and Hall, Julie and Fang, Bernard A.M. and Yee, Brendon J. and Wong, Keith K.H. and Grunstein, Ron R. and Lewis, Simon J. G.},
  issn         = {0885-3185},
  journal      = {MOVEMENT DISORDERS},
  keywords     = {Neurology,Clinical Neurology,melatonin,Parkinson's disease,randomized controlled trial,REM sleep behavior disorder,sleep disorders,THERAPY,RAMELTEON,PATIENT},
  language     = {eng},
  number       = {2},
  pages        = {344--349},
  title        = {Melatonin for rapid eye movement sleep behavior disorder in Parkinson's disease : a randomised controlled trial},
  url          = {http://dx.doi.org/10.1002/mds.27886},
  volume       = {35},
  year         = {2020},
}

Altmetric
View in Altmetric
Web of Science
Times cited: